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PEMPIAWAIAN DAN PENILAIAN EKSTRAK 
CATHARANTHUS ROSEUS 
 
ABSTRAK 
 
Satu ekstrak piawai Chantarantus roseus telah disediakan dengan 
menggunakan kaedah pengektrakan air dan ethanol. Kandungan bahan aktif ekstrak 
telah ditentukan dengan kaedah HPLC. Jumlah alkaloid Vinca yang digunakan 
sebagai bahan antikanser vinblastina (VBL) dan vincristina (VCR) telah ditentukan. 
Kandungan VBL dan VCR ditentukan untuk menilai sumbangan alkaloid-alkoloid 
ini terhadap aktiviti anti kanser ekstrak yang dihasilkan.  Pengesahan kaedah HPLC 
dilakukan berdasarkan prosedur yang terdapat dalam garispanduan USFDA dan 
ICH, dan didapati efisien dan   boleh dihasilkan semula.  Had minimum yang boleh 
dikesan untuk VCR adalah 0.25 g/ml danVBL ialah 0.5 g/ml. Kelinearan yang 
boleh diterima dipamerkan dengan pekali regresi (R
2
), iaitu 0.9999 hingga 1.  
Alkaloid pertama yang dielut  adalah  vinkristina dengan masa retensinya (Rt) adalah 
3.2.minit, diikuti dengan vindolina 3.56 minit, vinblastina 3.89 minit dan katarantina 
4.14 minit. Analisis HPLC daripada ekstrak Catharanthus roseus menunjukkan 
bahawa kandungan VBL adalah sama dalam semua kelompok ekstrak, namun 
demkian kepelbagaian dalam kandungan VCR turut diperhatikan. Kandungan 
ekstrak Catharanthus roseus yang terkira adalah rendah.  Keputusan ekstrak  etanol  
E1, E3, E4, E6  dijulat  sebagai  11.9µg/10mg, 9.0µg/10mg, 12.3µg/10mg dan 
14.4µg/10mg bagi vinblastina dan kandungan ekstrak air  W1, W3, W4, W6 dijulat 
sebagai 8.2µg/10mg,11.0µg/10mg,10.3µg/10mg dan 7.5µg/10mg bagi vinblastina. 
Keputusan ekstrak E1, E3, E4, E6, W1, W3, W4, W6 dijulat sebagai  19.9µg, 13.2µg, 
8.1µg, 26.3µg, 8.2µg, 13.1µg, 11.1µg, and 11.6 µg/10mg bagi vincristina. Meskipun 
fakta bahawa kandungan alkaloid wujud dalam  ekstrak Catharanthus roseus, 
namun ia adalah rendah apabila terdedah terhadap lini sel kanser yang berbeza,  
ekstrak WI, WII, W6 dan E6 mempamerkan aktiviti antikarsinogen. Kajian lini sel 
menunjukkan bahawa semua ekstrak yang terpilih untuk kajian ini adalah agen 
sitotoksik yang baik. Ekstrak etanol (E6) menunjukkan aktiviti kesitotoksikan yang 
boleh diterima terhadap sel kanser payu dara T47D (IC50 12 g/ml). Ekstrak air (W6) 
menunjukkan aktiviti yang boleh diterima terhadap kedua-dua lini sel kanser kolon 
 xxxiv 
 
HCT116 (IC50 10 g) dan HT29 (IC50 1.98 g). Ekstrak WI (etanol/air) juga aktif 
terhadap kedua-dua lini sel kanser kolon HCT116 (IC50 12.28 g) dan HT29 (IC50 
1.65 g). Ketoksikan oral akut adalah ketoksikan yang terhasil dalam tempoh tidak 
melebihi 24 jam, selepas sesuatu drug yang diberikan. Semasa ujian, pemerhatian 
tepi-sangkar (cage side observations, CSO) dilakukan secara berterusan untuk 
menentukan ketidaknormalan dan kemorbidan. Pembolehubah berat badan dan 
pengambilan makanan diawasi dengan teliti. Tiada perubahan dalam pembolehubah 
ini ditemui. Perubahan dalam pembolehubah ini diketahui sebagai tanda ketoksikan 
pertama. Kajian Ketoksikan Oral Akut Dos Tunggal menunjukkan bahawa ekstrak 
air dan etanol didapati tidak toksik jika diberi secara oral. Kajian angiogenesis 
menunjukkan bahawa larutan ekstrak Catharanthus roseus boleh merencat 
pertumbuhan saluran darah.  Aktiviti antiangiogenesis dalam ekstrak diuji 
menggunakan Model Aorta Tikus (Rat Aorta Model RAM).  Diperoleh bahawa, 
ekstrak ini merupakan agen antiangiogenesis yang baik pada kepekatan 10 g per 
ml. Oleh itu, daripada  kajian in vitro, in vivo dan ex vivo dapat disimpulkan bahawa 
ekstrak Catharanthus roseus adalah sitotoksik bagi lini sel kanser, tidak toksik 
apabila diberikan secara oral kepada haiwan dan juga mempunyai aktiviti 
antiangiogenesis.  
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STANDARDIZATION AND EVALUATION OF THE    
EXTRACT OF CATHARANTHUS ROSEUS 
 
ABSTRACT 
 
A standardized Catharanthus roseus extract has been prepared by water and 
ethanol method. The widely used anticancer Vinca alkaloids, vinblastine (VBL) and 
vincristine (VCR) present in the extract were determined by using HPLC. Contents 
of VBL and VCR were determined to assess the contribution of these alkaloids 
towards the anticancer activity of the extract. The method was validated in 
accordance to the procedure mentioned in the Guidelines of USFDA and ICH. The 
method was found efficient and reproducible. The minimum detectable limit of VCR 
was 0.25 g/ml and VBL was 0.50 g/ml. An acceptable linearity was exhibited 
with regression coefficient (R
2
) of 0.9999 to 1. The first eluted alkaloid was 
vincristine its retention time (Rt) was 3.2 minutes followed by vindoline 3.56 
minutes, vinblastine 3.89 minutes and catharanthine 4.14 minute. The content of 
VBL for the ethanol extracts E1, E3, E4 and E6 were 11.9µg/100mg, 9.0µg/100mg, 
12.3µg/100mg and 14.4µg/100mg of the dried extract. The contents of VBL 
determined in water extracts W1, W3, W4, W6 were 8.2µg/100mg, 11.0µg/100mg, 
10.3µg/100mg and 7.5µg/100mg. Amount of VCR present in Catharanthus roseus 
extracts E1, E3, E4, E6, W1, W3, W4, W6 was determined as 19.9µg, 13.2µg, 8.1µg, 
26.3µg, 8.2µg, 13.1µg, 11.1µg, and 11.6 µg/100mg of the dried extract. The study 
of the extract on cancer cells demonstrated good cytotoxic activity. Ethanol extract 
E6 showed acceptable cytotoxicity against breast cancer cells T47D (IC50 12 g/ml). 
Water extract W6 showed pronounced anticancer activity against colon cancer cell 
lines HCT116 (IC50 10 g/ml) and HT29 (IC50 1.98 g). Ethanol/water extract WI 
was also active against both colon cancer cell lines HCT116 (IC50 12.28 g) and 
HT29 (IC50 1.65 g). In single dose acute oral toxicity test, variables (body weight 
and feed intake) were carefully checked and no significant changes in these 
variables were initiated. There was no difference in physical state, behavior and 
response of the control and the treated groups. This study indicated that water and 
ethanol extracts were less toxic and can be administered orally. Antiangiogenesis 
study in Rat Aorta Model (RAM) revealed that the 10µg/ml solution of the alcohol 
 xxxvi 
 
water extract WI and Ethanol extract E6 of Catharanthus roseus inhibited the growth 
of blood vessels. The extracts appeared to be good antiangiogenic agent. The current 
study indicated that the Catharanthus roseus extract is less toxic when administered 
orally, exhibited cytotoxicity on cell lines and demonstrated good anti-angiogenesis 
activity.  
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CHAPTER 1 
 
 
GENERAL INTRODUCTION AND LITERATURE 
SURVEY 
 
 
1.1 CANCER  
 
Cancer is produced from a normal cell when it becomes abnormal.  Loss of 
growth control in a single cell causes trillions of cells to arise from a single cell 
(Bissell, 1981). The body has an unknown mechanism to eliminate cells losing 
growth control, but sometimes due to a variety of chromosomal changes, the cell 
cycle is driven crazy into nonstop division. The transcription factors such as E2F 
and c-myc are responsible for the cell cycle or cell growth, and involve in forcing 
cells into apoptosis or cell death. Thus, cell birth and cell death are initiated by the 
same pathway (Evan and Littlewood, 1998; King and Cidlowski, 1998). 
 
Cancer results from the genetic and epigenetic abnormalities in susceptible 
cells (Ponder, 2001; Houghton et al., 2007). In general, somatic mutations are 
involved, but it can also be inherited. Linkages are found through linkage-analysis 
of families with inherited predisposition to cancer (Wooster et al., 1995). Dietary 
and environmental factors also contribute in cancer formation (Doll and Peto, 1981; 
Houghton et al., 2007). Cancer is proven to be a potentially fatal disorder that 
involves proliferation, transformation and deregulations of apoptosis. Cancer genes 
initiate extensive changes in cellular structure and cellular functions. These changes 
increase sensitivity to growth signals and insensitivity to growth-inhibitory signals, 
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decrease apoptosis and increase potential to replicate, generate angiogenesis and 
metastasis (Hanahan and Weinberg, 2000; Ichikawa et al., 2007). 
 
1.1.1 Oncogenes and tumor suppressor genes 
Three types of genes are known to take part in development of cancer. The 
first type is oncogenes, is mutated or over expressed from normal proto-oncogenes. 
These are positive regulators of cell growth for example, n-myc in neuroblastoma, c-
erb-B2 in breast cancer and k-ras in pancreas cancer. The second type is known as 
tumor suppressor genes (TSGs). These are negative regulators of cell growth 
(Knudson, 1971). The third type is DNA repair genes (Cleaver, 1994). The tumor 
originates from the activation of oncogenes and the inactivation of tumor-suppressor 
genes.  
 
Over hundred oncogenes have been identified and can be defined as gene-
encoding products. The increased activity of oncogenes leads to increased 
proliferation. The deregulation of cancer genes results in a wide range of changes in 
cellular function and structure, all are contributing in various ways to malignancy 
(Hanahan and Weinberg, 2000). Some oncogenes, such as ras, myc and erb are 
identified as the human homologs of the viral transforming genes. Cellular genes 
become activated-oncogenes when these are incorporated into the viral genome 
(Harkin and Johnston, 2005).  
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1.1.2 Molecular natural cell cycle clock 
A molecular natural clock instructs the cell when to replicate its DNA and 
when to divide. Some proteins regulate the timings of events occur in the cell cycle. 
The loss of control on timing leads towards cancer (Houghton et al., 2007; Ichikawa 
et al., 2007). A protein known as cycline is the oscillator that runs the molecular 
clock. The cellular concentration of cyclin increases till the time of cell division and 
then suddenly decreases (Evan et al., 1983). One specific enzyme known as cyclin-
dependent kinase (cdk) also takes active part in the clock mechanism. Then another 
component protease (in the form of a proteasome) reset the clock (Glotzer et al., 
1991; King et al., 1996). The cell cycle time for human tumors is around two days 
to several weeks (Wilson et al., 1988; Basse et al., 2002).  
 
1.1.3 A brief history of treatment of cancer 
In early days, the bacterial toxins were used in cancer treatment. It was 
based on host–tumor interactions, which opens the way to anti-angiogenesis and 
immune approaches. Modern research is developing a combination of complex 
strategies for growth and death control systems within the tumor cell. However, the 
development of low molecular-weight anticancer drugs and new strategies are likely 
to be continued. Currently the treatment for cancer ailment involves a combination 
of surgery, radiotherapy and chemotherapy. Natural products from plant origin play 
a very significant role in cancer therapy. One of the flowering plants, Catharanthus 
roseus is fundamentally cytotoxic and inhibits proliferation by exhibiting a very 
unique strategy, known as cell cycle specificity (Johnson et al., 1963). A brief 
history of clinical cytotoxic drugs is summarized in the following Table 1.1 
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              Table 1.1 A brief history of clinical cytotoxic drugs 
 
 
                      
 
 
 
 
 
No 
 
Drug 
Approximate 
Year of 
introduction 
 
 
 
 
 
 
 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
 
 
 
 
 
 
 
 
 
WHO updated 
the list into 
three categories 
 
Category 1 
Essential drugs 
 
Bleomycin 
Chlorambucil 
Cisplatin 
Cyclophosphamide 
Cytarabine 
Dactinomycine 
Daunorubicin 
Doxorubicin 
Etoposide 
Fluorouracil 
Mercaptopurine 
Methotrexate 
Prednisolone 
Procarbazine 
Tamoxifen 
Vinblastine 
Vincristine 
 
Category 2 
12 drugs  
(See Martindale, 
2007) 
 
Category 3 
Non essential 
13 drugs 
(See Martindale, 
2007) 
 
 
 
1999 
 
 
1999 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1999 
 
 
 
 
1999 
 
 
 
No 
 
Drug 
Approximate 
Year of 
introduction 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
 
 
 
 
 
 
 
25 
26 
27 
28 
 
N Mustard 
Methotrexate 
Chlorambucil 
Thioguanine 
Cyclophosphamide 
Vinblastine 
5-Fluorouracil 
Vincristine 
Melphalan 
Daunorubicin 
Cytarabine. 
Bleomycin 
Doxorubicin 
Mitomycin 
Dacarbazine 
BCNU 
Cisplatin 
Etoposide 
Teniposide 
Amsacrine 
Carboplatin 
Epirubicin 
Mitoxantrone 
Paclitaxel 
 
 
WHO recognized 
this list of  24 
essential drugs  
 
 
Gemcitabine 
Docetaxel 
Topotecan 
Irinotecan 
 
1948 
1953 
1956 
1958 
1959 
1960 
1961 
1962 
1964 
1965 
1970 
1974 
1976 
1977 
1978 
1980 
1978 
1979 
1980 
1981 
1984 
1987 
1989 
1992 
 
 
 
1994 
 
 
 
1995 
1996 
1997 
1998 
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1.2 DRUG DISCOVERY OF NATURAL FLORA 
Nature contributes a very significant role in medicinal therapy. It is likely to 
continue to be a source of new drugs in this modern era (Shah and Kaye, 2003). 
Natural compounds are complexes of well kept secrets of nature. Researchers are 
disclosing these wonders by using different techniques through available knowledge 
in the field of drug discovery to select out the compound of their interest. Current 
high throughput instrumental development had made drug discovery and 
development process more efficient (Drager, 2002; Houghton, 2002; McCally, 
2002; Molyneux et al., 2002; Stockigt et al., 2002; Chen et al., 2004; Balunas; 
King-Horn, 2006).  
 
1.2.1 Lead structures of the synthetic compounds  
Lead structures of most synthetic chemicals are based on structure of natural 
products (Mann, 2002). The supremacy of natural products over synthetic 
compounds is due to their colossal structural and chemical diversity. ―About 40% of 
the chemical scaffolds found in natural products are not available in today‘s 
medicinal chemistry‖ (Muller-Kuhrt, 2003). More than 50% of the drugs in clinical 
use are obtained from plant origin (Mann, 2002). According to the world health 
organization (WHO), up to 80% of people living in developing countries are 
following Traditional Medicine for their healthcare. People believe that majority of 
the natural products used are pharmacologically safer, more affordable and have in- 
built advantage that they hit multiple targets. (Kong and Liu, 2006)  
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1.2.2 “Natural Inhibitor of Carcinogenesis” 
More than 10 countries have collaborated with the United States to conduct 
research under the project of ―Natural Inhibitor of Carcinogenesis‖ and listed more 
than 250 compounds out of 5000 plant samples as potential cancer 
chemoprevention. The European Parliament passed a new legislation for European 
Union member nations to facilitate traditional medicine makers in terms of 
determination of efficacy. Canada opened a new Natural Health Products 
Directorate programme in January 2004. Pakistan, India, and Brazil are also 
developing botanical-drug research and testing centers (Kong and Liu, 2006). More 
than 2000 species grown in Malaysia are reported to have medicinal value (Jaganath 
and Ng, 2000). The climate of Malaysia is also suitable for the growth of 
Catharanthus roseus (C. roseus).  
 
1.3 CATHARANTHUS ROSEUS (C. ROSEUS) 
Catharanthus roseus is an ever blooming sub-tropical shrub. It was 
originally indigenous to Madagascar. It is now widely grown and used as 
indigenous medicine all over the world (Yarnell and Philhower, 2005).  
 
1.3.1 Nomenclature of Catharanthus roseus     
Its official name is Catharanthus roseus Linn G. Don, from family 
Apocynaceae (Leveque and Jehl, 2007; Magnotta et al., 2007). Its synonym is Vinca 
rosea Linn, other included names are Lochnera rosea Reichb (Daniel, 2000), 
Periwinkle, Baramasi and Rattan-jot (Chopra et al., 1956 and1986). In Pakistan this 
plant is locally named as Sadaa bahaar (ever blooming). In Malaysia it is locally 
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known as Kemuning cina (Siddiqui, 2010). It produces potent anticancer Vinca 
alkaloids (Cutts et al., 1960: Johnson, et al., 1963).  
                         
 
 
                       
            
 
       Figure 1.1 Catharanthus roseus 
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1.3.2 Ethno-medical uses of Catharanthus roseus. 
Most of the useful drugs derived from plants have been discovered by 
follow-up of the ethno medical uses (Farnsworth et al., 1985; Dutcher et al., 2000). 
In 1910, Catharanthus roseus was reported to be useful in Brazil as infusion of the 
leaves for mouth washes and toothaches, for the cleansing and healing of chronic 
wounds and also used in hemorrhage and scurvy (Synold, 2005; Johnson et al., 
1960). In British West Indies, it has been used to treat diabetic ulcers (Johnson et 
al., 1960) In the Philippines; it has been used orally in the treatment of 
hyperglycemia and hypertension (Garcia, 1953).  
 
In the forests of Madagascar, local people have been using decoction of the 
roots of Catharanthus roseus for the treatment of parasitic worms (Norscia and 
Borgognini-Tarli, 2006). Water extract of Catharanthus roseus was used for 
bleeding arrest, diabetes and fever or rheumatism (Ross, 2003). The leaves of the 
plant were chewed to suppress the sensations of hunger and fatigue (Ross, 2003; 
van der Heijden et al., 2004; Ferreres et al., 2008). The herbal and other 
preparations of C. roseus have been used for cancer and hypertensive treatment 
since ancient times (Hardman and Limbird, 2001). 
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1.4 VINCA ALKALOIDS AND OTHER COMPOUNDS    
     PRESENT IN CATHARANTHUS ROSEUS (C. ROSEUS)  
Antihypertensive/antiarrhythmic alkaloid ajmalicine and tranquillizer 
alkaloid serpentine and anticancer alkaloids vincristine and vinblastine isolated from 
Catharanthus roseus (C. roseus) were introduced as Vinca alkaloids (Hardman and 
Limbird, 2001). Developments in cancer treatment started in the 20th century 
(Baguley, 2002). 
 
More than hundred indole Vinca alkaloids are reported from Catharanthus 
roseus (Heijden et al., 2004; Hisiger and Jolicoeur, 2007). Twenty Indole-indoline 
dimeric alkaloids are more important. They are listed in Table 1.2. Only serpentine 
as tranquillizer (Iwase et al., 2005), ajmalicine as anti-arrhythmic (Srivastava et al., 
2006) and vinblastine, vincristine and 3, 4- anhydrovinblastine as anti-cancer were 
marketed (Heijden, et al. 2004). Vindoline and catharanthine are the precursors in 
the biosynthetic pathways of dimeric indole alkaloids vinblastine and vincristine 
(Noble, 1990; Jolicoeur, 2007). Catharanthus roseus plant gains more interest due 
to its anticancer alkaloids (Sousa et al., 2008). A list of anticancer alkaloids is 
mentioned bellow in Table 1.3. 
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Table1.2 Important alkaloids reported from Catharanthus roseus  
 
Alkaloids Old name Source Empirical 
Formula 
Vinblastine Vincaleukoblastine Whole 
plant 
C46H58N4O9 
Vincristine Leurocristine and 
Vincaleurocristine 
Arial parts C46H56N4O10 
Vindesine Vindesine Arial parts C43H57N5O11S 
Leurosine Leurosine Arial parts C46H58N4O9 
Ajmalicine Raubasine Flowers C21H24N2O2 
Lochnerine Lochnerine Flowers C20H24N2O2 
Lochnericine Lochnericine Flowers C21N24N2O2 
Catharanthine Catharanthine Flowers C21H24N2O2 
Serpentine Serpentine Flowers C21H22N2O3 
Vindoline Vindoline Arial parts C25H32N2O6 
Vindolinine Vindolinine Arial parts C21H24-6N2O2 
Reserpine Reserpine Arial parts C23H40N2O9 
   
       (Johnson, et al., 1960; Daniel, 2000; British Pharmacopoeia, 2000; Dutta   
       et al., 2005) 
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Table 1.3 Frequently used salts of anticancer alkaloids from Catharanthus    
               roseus     
 
   (Johnson, et al., 1960; Daniel, 2000; British Pharmacopoeia, 2000; Dutta et    
    al., 2005) 
 
 
 
 
 
 
Salts of 
anticancer 
alkaloids 
Brand name Molecular 
weight of 
salt 
Empirical formula 
Vinblastine            
sulfate 
Exal,Velban Velbe 
Velsar 
909.1 
(sulfate) 
C46 H58 N4 O9,H2SO4 
Vincristine        
sulfate 
 
Oncovine, Vincasar, 
Kyocristine,Vincosid, 
Vincrex 
 
923 
(sulfate) 
C46H56N4O10,H2SO4 
Vindesine           
sulfate 
Eldistine, Fildesine 852 
(sulfate) 
C43H57N5O11S 
 
Vinorelbine 
ditartrate 
 
Navelbine 
 
 
1079 
(di tartrate) C45H54N4O8,2C4H6O6 
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The anticancer activity of the C. roseus is mainly dependent on alkaloids 
such as vincristine, vinblastine, vindesine and vinorelbine, but the presence of 
phenols (Piovan and Filippini, 2007; Mustafa and Verpoorte, 2007; Ferreres et al., 
2008) and antioxidants (Misra and Gupta, 2006; Abduljaleel and Gopi, 2008) also 
contribute highly towards anticancer activity. The known compounds other than 
alkaloids and their mechanism of action are discussed in Section 1.10.2. 
 
1.4.1 Discovery of anticancer alkaloids from C. roseus 
  Vinca alkaloids were isolated form C. roseus leaves in the late 1950s 
independently by two groups; Professor Noble working at the Western University of 
Ontario, Canada, and  the other researchers at the Eli Lilly research laboratories in 
Indianapolis, USA (Noble, 1958 and 1990; van der Heijden et al., 2004). Vinca 
alkaloids were scientifically studied initially as oral hypoglycemic agents (Johnson 
et al., 1963).  
 
Robert Noble was working in Canada on some hypoglycemic oral 
compound found in Catharanthus roseus, (C. roseus) not grown in Canada (Tailor 
and Farnsworth, 1975). C. roseus extract solution when injected into mice caused 
immune suppression (Noble et al., 1958; Duffin, 2002). It indicated the extract can 
induce pronounced activity without any toxic effect (Johnson et al., 1963; Yarnell 
and Philhower, 2005).  
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1.4.2 Earliest chemotherapeutic agents  
Catharanthus roseus is the only source for vinblastine and vincristine.  
Catharanthus roseus produced around 130 indole alkaloids, but a full picture of its 
biosynthetic pathway has yet to be elucidated (Zeffrin, 1984; El-Sayed and 
Verpoorte, 2007). Before 1961, vinblastine was the only anticancer drug 
commercially available for cancer treatment from C. roseus. In March 1961, Eli 
Lily announced the commercial availability of a new anticancer compound called 
leurocristine, which was the former name of vincristine (Johnson et al., 1960). 
Vinblastine and vincristine are among the earliest agents developed for cancer 
therapy. They are approved for cancer treatment for more than 30 years and remain 
widely used in anticancer therapy.  
 
1.4.3 Cancers treated by Vinca alkaloids 
Vinca alkaloids and their derivatives act as mitotic inhibitors (Rowinsky and 
Donhower, 1996). Vinblastine and vincristine have been used as chemotherapeutic 
agents in the treatment of a wide range of tumors, particularly childhood tumors, 
leukemia and lymphomas (Riyaz and Stanley 2003; Synold, 2005; Levêque and 
Jehl, 2007), Hodgkin‘s disease (Svoboda, et al., 1959; Levêque and Jehl, 2007) and 
testicular teratoma (Mann, 2002; Synold, 2005). It is also effective in treating breast 
carcinoma, nephroblastoma, brain tumors, lung cancer, leiomyosarcoma, cervix 
cancer, alimentary tract tumor (Pui and Evans, 1998) and Kaposi‘s sarcoma (Kaplan 
et.al., 1986; Gill et al., 1991; Tulpule and Matheny, 1998). Different cancers treated 
by Vinca alkaloids are listed in Table 1.4 
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               Table 1.4 Cancers treated by Vinca alkaloids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Mac Lenna and Cusack, 1985; Boccardo et al., 1989; Daniel, 2000; British  
Pharmacopoeia, 2002; Extra Pharmacopoeia, 2002; Ichikawa et al., 2007) 
 
 
 
 
 
 
 
 
 
Alkaloid 
 
Uses 
 
 
Vinblastine 
Mitotic inhibitor 
 
 
Leukemia, Hodgkin's lymphoma and germ cell cancer, 
Kaposi's sarcoma, bladder, breast and lung cancer. 
 
 
Vincristine 
Topoisomerae 
inhibitors 
 
Ovarian cancer, leukemia, Hodgkin's lymphoma, 
Wilm's tumor, multiple myeloma, breast and lung 
cancer. 
 
 
Vinorelbine 
(Navalbine) 
 
Breast, non-small cell lung cancer, gastrointestinal 
cancer 
 
 
Vinoflunine 
Phase-II clinical 
trials 
 
 
Phase-II clinical trials bladder, non-small cell lung 
carcinoma and breast cancers. 
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1.4.4 Sulfate and ditartrate salts of Vinca alkaloids  
In treatment of the cancer, either of the Vinca alkaloids is prescribed in 
combination with the other cytotoxic drugs. A collection of alkaloids from 
Catharanthus roseus (C. roseus) is presented in Table1.2. C. roseus produced 
various monoterpenoid indole alkaloids (MIAs) (Ichikawa et al., 2007). They are 
utilized in salt form as listed in Table1.3. The sulfate salts of vinblastine, vincristine 
and vindesine are administered via intravenous route. Vinorelbine ditartrate salt 
(Novelbine) is administered orally (Degardin et al., 1994; Extra Pharmacopoeia, 
2002). A semi synthetic fluorinated Vinca alkaloid is produced through change in 
the catharanthine moiety of vinblastine (Kruczynski and Hill, 2001; Jacquesy, 
2006).  
 
1.5 STRUCTURE OF VINCA ALKALOIDS                
A group of researchers at Eli Lilly discovered the structures and revealed the 
clinical activity of vincristine and vinblastine (Edwards, 1994). Vinca alkaloids are 
identical in structure with difference in the group attached to the nitrogen at position 
1 at which vincristine possesses a labile N- formyl group and vinblastine has a 
stable methyl group Figure 1.2. D ring is a small portion of Vinca molecule which is 
extremely sensitive in term of overall biological properties and tubulin interactions 
(Jacques, 2001).  
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Fig 1.2 Chemical structure of Vinca alkaloids 
 
 
 
Alkaloids R1 R2 R3 
Vinblastine -CH3 -CO2CH3 -OCOCH3 
Vincristine -CHO -CO2CH3 -OCOCH3 
Vindesine -CH3 -CONH2 -OH 
Vinorelbine -CH3 -CO2CH3 -OCOCH3 
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1.5.1 Structural difference and clinical activity  
There are minor structural differences present between anticancer Vinca 
alkaloids and they behave in the same way with the drug-tubulin interaction but 
their toxicity and spectrum of clinical activity is significantly different from each 
other. (Himes et al., 1976; Owellen et al., 1977) 
 
1.5.2 Derivatives of Vinca alkaloids 
In combination with other anticancer therapies, vinblastine and vincristine 
are given for a curative purpose (Levêque & Jehl, 2007). From vinblastine 
(Oncovin) and vincristine (Velbe), a large number of derivatives have been formed. 
They are modified in the vindoline moiety (mido derivative). Vindesine 
(deacetylvinblastine amide) (Barnett et al., 1978) was registered in Europe in 1980. 
Vindesine is not approved in the United States, and in France. It is used in the 
treatment of aggressive forms of non-Hodgkin lymphomas in combination with 
other anticancer drugs. 
 
In 1980s a semi synthetic derivative is introduced as vinorelbine nor-5′-
anhydrovinblastine (Navelbine). It is invented by the pharmacist Pierre Potier and 
his team in France, produced by changing the catharanthine moiety of vinblastine. 
Vinorelbine is given in palliative treatment of advanced nonsmall-cell lung cancer, 
refractory lymphoid malignancies and advanced breast cancer. Vinorelbine gives 
greater therapeutic activity when given as adjuvant (or postoperative) treatment 
associated with cisplatin in patients with resected non-small-cell lung cancer 
(Winton et al., 2005; Douillard et al., 2006). 
 
                                                                  18 
 
Vinflunine is a fluorinated derivative of vinorelbine. It is in the process of 
clinical development ( Kruczynski & Hill, 2001; Bennouma et al., 2005). The 
substitution of fluorine in the structure of natural products has been proven 
beneficial. The fluorination increases the lipophilic profile of a molecule, which can 
be more effective (Thomas, 2006). Novel vinflunine (Javlor) is under clinical trial 
(Kruczynski and Hill, 2001; Jacquesy, 2006) and advanced to the phase III clinical 
trials (Shnyder, 2004). Vinflunine hold a potent antiangiogenic effect (Holwell et 
al., 2001).                    
 
1.6 MODE OF ACTION OF VINCA ALKALOIDS 
The mechanism of antineoplastic activity is worked during cell mitosis 
(George et al., 1965). Vinca alkaloids are mitotic inhibitors (Himes, 1991; da Rocha 
et al., 2001; Honore et al., 2003). These agents target microtubules. They are the 
structural backbone of both normal and abnormal cells. Microtubules are polymers 
of long tube shaped dynamic structures. They are constantly growing and shortening 
(Mitchison and Kirachner, 1984). 
 
Microtubules contribute essential roles in construction and function of the 
mitotic spindle. They actively take part in many cellular events, including cellular 
organization, cell division, intracellular transport, intracellular transfer of signals, 
neurotransmission, and the transmission of signals from the cell-surface-receptors to 
the nucleus (Dutcher and Novik, 2000).  
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1.6.1 Target of Vinca alkaloids for anticancer activity 
Tubulin is one of the essential proteins for chromosomal segregation. The 
tubulin- microtubule system is an important target for anticancer therapy (Jordan 
and Hadfield, 1998; Houghton, 2002). Hydrophobic Vinca alkaloids bind to tubulin 
in a reversible manner (Zhou and Rahmani, 1992). The Vinca alkaloids inhibit the 
microtubule polymerization at high non-physiologically relevant concentrations 
(Jordan et al., 1991; Dhamodharan, et al., 1995). Vinca alkaloids act by binding to 
the micro-tubular proteins of the spindle and arresting mitosis at the 
metaphase/anaphase transitions leading to apoptosis (Nagan, 2000; Kruczynski et 
al. 2002).  
 
The mechanism of the mitotic blockage is not well known (Okouneva et al, 
2005; Weaver and Cleveland, 2005), the Vinca alkaloids interfere with the function 
of microtubules in axons, which mediates the neuronal vesicle transport (Dumontet 
et al., 1999; Bacher et al., 2001). The research is performed on an array of 
chemically diverse antimitotic and microtubule targeting agents. They depolymerize 
microtubules of newly developed vascular system and stop the blood supply to 
tumor (Okuneva et al., 2003; Honore et al., 2003; Jordan and Wilson, 2004). The 
function of Vinca alkaloids as angiogenesis agent is discussed in chapter 6.  
 
1.6.2 Vinca alkaloids as mitotic inhibitors during cell cycle 
 There are two prominent phases occur in mammalian cell division. One is 
known as synthetic or S phase and the other is mitosis or M phase. There are two 
gaps G1 and G2 occur between S phase and M phase. Vinca alkaloids function as 
mitotic inhibitors between G2 and M phase of the cell cycle. (Musunru and Hinds, 
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1997)   The transitions from G1-phase to S-phase, and from G2-phase to M-phase, 
are controlled by a system of cyclin-dependent kinases (cdk), cyclins and 
phosphatases (Houghton et al., 2007; Ichikawa et al., 2007). The cell cycle clock is 
demonstrated in Figure 3.      
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        Figure 1.3 The cell cycle clock 
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The known mechanism of drug action is to arrest cells at the metaphase by 
interfering with the assembly or disassembly of - and β- tubulin into microtubules 
and inhibits tubulin polymerization (Rowinsky and Donhower, 1996). These drugs 
target β-tubulin subunit of -/β- tubulin heterodimers, inhibiting the addition of 
heterodimers onto growing microtubules, hence, preventing polymerization of 
microtubules (Musunru and Hinds, 1997; Jordan and Wilson, 1998).  
 
1.6.3 Activity of Vinca alkaloids in high and low concentration 
 
At high concentrations, the Vinca alkaloids cause complete microtubule de-
polymerization. At low concentrations de-polymerization does not occur but there is 
sufficient alteration in the dynamics of tubulin loss or addition at the ends of mitotic 
spindle. It prevents the spindle from carrying out its function of attaching to and 
segregating the chromosomes, and cause cell arrest during mitosis (Jordan et al., 
1992; Jordan, 2002; Jordan and Wilson, 2004). Prolonged arrest finally leads to cell 
death, either in mitosis or after an ultimate escape from mitotic arrest (Jordan and 
Wilson, 1998).   
 
Lower concentrations of microtubule-targeted drugs can suppress dynamics 
of microtubule without changing mass of microtubule (Okouneva et al., 2003). 
Tubulin binding and disruption of the cell membranes simultaneously occur due to 
interference with the lipid bi-layer at the same concentration ((Rowinsky and 
Donhower, 1996).  
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1.6.4 Special Vinca-specific high-affinity and low-affinity sites  
Each heterodimer of tubulin possesses special Vinca-specific high-affinity 
and low-affinity sites. These binding sites are different from the interacting sites of 
other drugs such as taxanes (Rao et al., 1992; Rao and Krauss et al., 1994). Binding 
to the high affinity sites decreases the rate of dissociation and association of tubulin 
dimers of the microtubules (Jordan et al. 1986). Binding to the low-affinity sites 
appears to be responsible for disruption of the microtubule configuration, leading to 
disintegration (Jordan et al., 1986).  
 
Despite the above mentioned promising anticancer activity, these alkaloids 
have many problems during their uses. The drug resistance, toxicity, and low 
specificity are major difficulties in the treatment of cancer (de Mesquita et al., 
2009). A brief account on these problems is discussed as follows. 
 
1.7 CELL RESISTANCE AGAINST VINCA ALKALOIDS 
The efficacy or activity of Vinca alkaloids decreases when cancer cells 
develop resistance against anticancer drugs (Dumontet and Sikic, 1999). When 
cancer cells develop clinical resistance to one drug, the simultaneous resistance to 
several other structurally and mechanistically unrelated drugs is also induced. 
Clinical resistance reduces the concentration of the drug in the target cell, which in 
consequence reduces activity and decreases the clinical effectiveness of drug 
(Husain and Wozniak, 1993; Hunter, 1997; ACPE, 2002).  
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1.7.1 Classical multiple drug resistance (MDR) of cancer cells   
         to natural hydrophobic drug 
Vinca alkaloids are comparatively more hydrophobic in nature. Resistance 
development of cancer cells to natural hydrophobic drugs are known as classical 
multi drug resistance. Study of cancer cells in culture with vinblastine, paclitaxel or 
doxorubicin frequently results in multi drug resistance due to expression of ATP-
dependent efflux pumps with broad drug specificity. Family of ATP-binding 
cassette (ABC) transporters is responsible for efflux pumps. It is further divided into 
seven subfamilies (ABCA-ABCG). The ABC transporter P-glycoprotien (P-gp) is 
the product of the ABCB1 or mdr1-gene (Tsuruo et al., 1972; Kolars et al., 1992; 
Gottesman et al., 2002).  
 
There are different mechanisms of resistance including P-glycoprotien efflux 
pump and multi drug resistance protein (MRP). These proteins are transmembrane 
transporters which are also responsible for the rapid efflux of intracellular 
chemotherapeutical agents. Over expression of these proteins indicate the less 
concentration of intracellular Vinca alkaloids and reduction in cytotoxicity. In brief, 
the development of multiple drug resistance (MDR) is common for Vinca alkaloids 
due to the following reasons: 
 
1. Over expression of transmembrane efflux pump system known as P-
glycoprotein (P-gp) (Cole and Deeley, 1998; Bardelmeijer et al., 2000; 
Bacher and Nickel, 2001). 
 
2. The action of multi-drug resistance-associated proteins (MRP) (Fardel et al., 
1996; Cole and Deeley, 1998; Bardelmeijer et al., 2000; Bacher and Nickel, 
2001). 
